First liquid chromatographic method for the simultaneous determination of amiodarone and desethylamiodarone in human plasma using microextraction by packed sorbent (MEPS) as sample preparation procedure

被引:20
作者
Rodrigues, Marcio [1 ,2 ,3 ]
Alves, Gilberto [2 ,3 ]
Rocha, Marilia [2 ,4 ]
Queiroz, Joao [3 ]
Falcao, Amilcar [1 ,2 ]
机构
[1] Univ Coimbra, Fac Pharm, Pharmacol Lab, P-3000548 Coimbra, Portugal
[2] Univ Coimbra, CNC Ctr Neurosci & Cell Biol, P-3004517 Coimbra, Portugal
[3] Univ Beira Interior, CICS UBI Hlth Sci Res Ctr, P-6200506 Covilha, Portugal
[4] Coimbra Univ Hosp, Pharmaceut Serv, P-3000075 Coimbra, Portugal
来源
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 2013年 / 913卷
关键词
Amiodarone and desethylamiodarone; Microextraction by packed sorbent; HPLC; Bioanalytical method validation; Human plasma; Therapeutic drug monitoring; TANDEM MASS-SPECTROMETRY; METABOLITE DESETHYLAMIODARONE; SERUM CONCENTRATIONS; DESETHYL METABOLITE; URINE SAMPLES; TOXICITY; POPULATION; EXTRACTION; PHARMACOKINETICS; EFFICACY;
D O I
10.1016/j.jchromb.2012.11.028
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
For the first time a simple and fast high-performance liquid chromatography (HPLC) method using a novel sample preparation procedure based on microextraction by packed sorbent (MEPS) was developed and validated for the determination of amiodarone (AM) and its main metabolite desethylamiodarone (DEA) in human plasma. Chromatographic separation of the analytes (AM and DEA) and tamoxifen, used as internal standard (IS), was achieved within less than 5 min on a LiChroCART Purospher (R) Star C-18 column (55 mm x 4 mm, 3 mu m). The mobile phase consisting of 50 mM phosphate buffer with 0.1% formic acid (pH 3.1)/methanol/acetonitrile (45:5:50, v/v/v) was pumped isocratically at a flow rate of 1.2 mL/min. The detection was carried out at 254 nm. Calibration curves were linear (r(2) >= 0.9976) in the ranges of 0.1-10 mu g/mL for AM and DEA. The limits of quantification were established at 0.1 mu g/mL for AM and DEA. The overall imprecision did not exceed 6.67% and inaccuracy was within +/- 9.84%. The overall mean recovery of AM and DEA ranged from 58.6% to 68.2%. Neither endogenous nor tested exogenous compounds were found to interfere at retention times of the analytes (AM and DEA) and IS. This new MEPS/HPLC method was also applied to real samples obtained from polymedicated patients receiving AM therapy. Thus, this bioanalytical method seems to be a useful tool for therapeutic drug monitoring of patients under AM treatment and also to support other clinical pharmacokinetic-based studies involving this drug, such as bioavailability/bioequivalence studies. (c) 2012 Elsevier B.V. All rights reserved.
引用
收藏
页码:90 / 97
页数:8
相关论文
共 50 条